Pfizer price bias bearish after news Pfizer is buying stake in French vaccine maker Valneva
Technical Analysis Summary Pfizer Inc.: Sell
| Indicator | Value | Signal |
| RSI | Buy | |
| MACD | Sell | |
| Donchian Channel | Sell | |
| MA(200) | Sell | |
| Fractals | Sell | |
| Parabolic SAR | Sell |
Chart Analysis
The technical analysis of the Pfizer stock price chart on daily timeframe shows #S-PFE,Daily is retracing under the 200-day moving average MA(200) which has levelled off. RSI is in oversold zone. We believe the bearish momentum will continue after the price breaches below the lower boundary of Donchian channel at 46.26. This level can be used as an entry point for placing a pending order to sell. The stop loss can be placed at 50.40. After placing the order, the stop loss is to be moved every day to the next fractal high, following Parabolic signals. Thus, we are changing the expected profit/loss ratio to the breakeven point. If the price meets the stop loss level (50.40) without reaching the order (46.26), we recommend cancelling the order: the market has undergone internal changes which were not taken into account.
Fundamental Analysis of -
Pfizer is buying stake in French vaccine maker Valneva. Will the Pfizer stock price rebound?
Pfizer has agreed to pay €90.5mn for an 8.1% stake in Valneva, in a move that will bolster the French vaccine company’s Lyme disease program. Pfizer is buying the stake at a price of €9.49 a share — a 20% premium to Valneva’s closing price on Friday of €7.94. The proceeds from the transaction disclosed on Monday will go towards developing a Lyme disease joint program. Valneva will fund 40% of the remaining shared development costs, Pfizer will pay Valneva tiered royalties from 14% to 22%, which will be complemented by up to $100 million in payments to Valneva if certain sales milestones are reached. There is currently no vaccine available for Lyme disease, a tick-borne infection that can prove seriously debilitating. Expectations of rising sales are bullish for company’s stock price. However the current setup is bearish for the stock.